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Abstract 
Galactokinase catalyses the phosphorylation of α-D-galactose and some structurally related 
monosaccharides.  The enzyme is of interest due to its potential as a biocatalyst for the production 
of sugar 1-phosphates and due to its involvement in the inherited metabolic disease type II 
galactosemia.  It has been previously shown that a region (residues 231-245) in human galactokinase 
often has altered mobility when active site residues are varied.  We hypothesised that the reverse 
may be true and that designing changes to this region might affect the functioning of the active site 
of the enzyme.  Focussing on four residues (Leu-231, Gln-242, Glu-244 and Glu-245) we conducted 
molecular dynamics simulations to explore the effects of changing these residues to glycine or 
serine.  In most cases the variations resulted in local changes to the 231-245 region and global 
changes to the root mean squared fluctuation (RMSF) of the protein.  The four serine variants were 
expressed as recombinant proteins.  All had altered steady state enzyme kinetic parameters with α-
D-galactose as a substrate.  However, these changes were generally less than ten-fold in magnitude.  
Changes were also observed with 2-deoxy-α-D-galactose, α-D-galactosamine and α-D-talose as 
substrates, including (in some cases) loss of detectable activity, suggesting that these variations can 
tune the specificity of the enzyme.  This study demonstrates that activity and specificity of human 
galactokinase can be modulated by variations designed to affect active site flexibility.  It is likely that 
this principle can be generalised to other enzymes. 
 
Keywords:  enzyme engineering; GHMP kinase; molecular dynamics; protein flexibility; α-D-
galactose;  
  
  
Introduction 
It has become well-established that protein mobility is critical for function, including catalysis [1, 2].  
This mobility can be local to specific elements of the protein’s structure, or more global.  In 
particular the mobility of active site residues can be important in mediating catalysis and 
determining the specificity of enzymes [1, 3-5].  However, other structural elements can indirectly 
influence the mobility of the active site and thus need to be considered.  Effects on mobility are 
often over-looked when protein engineering is undertaken to alter the specificity or activity of 
enzymes.  This oversight may be a cause of the failure of some enzyme engineering projects to 
achieve their full potential. 
We have previously shown that several regions which are not part of the active site are critical for 
controlling specificity and catalysis in human galactokinase (EC 2.7.1.6) [6-10].  This enzyme is a 
member of the GHMP kinase family and catalyses the first committed step of the Leloir pathway, the 
ATP-dependent phosphorylation of α-D-galactose [11-13].  The human enzyme is relatively highly 
selective – only α-D-galactose, α-D-galactosamine, 2-deoxy-α-D-galactose and α-D-talose are known 
to be substrates [8, 9, 14].  One region, located around Try-379, influences the flexibility of residues 
which form the active site.  This appears to control specificity:  variation of Tyr-379 broadens the 
range of substrate phosphorylated by the enzyme, albeit at a significant cost in terms of activity [9].  
This region has also been targeted in bacterial galactokinases which are, in general, more 
promiscuous than the human enzyme [10].  Variation of the equivalent tryptophan residue in 
Lactococcus lactis and Escherichia coli galactokinases have resulted in considerable broadening of 
the substrate range combined with reasonable activity [15-20].  These broad specificity 
galactokinases are able to catalyse the site and stereo-specific phosphorylation of a wide range of 
monosaccharides, reactions which may have utility in in vitro glycorandomisation and the 
subsequent development of new drug-like molecules which incorporate sugar moieties [21]. 
Two other critical regions have recently been identified in human galactokinase.  Residues 174–179 
and 231–240 are both affected by variations to active site residues, despite these regions not being 
part of the active site.  Molecular dynamics simulations predicted that the structure and dynamics of 
both of these regions are disrupted when Arg-37 or Asp-186 are varied.  The propensity for α-helical 
structure in the 231-240 region is reduced by variation of active site residues, whereas the 174-179 
region becomes more likely to form an ordered turn rather than random coil [6].  Arg-37 and Asp-
186 are implicated in the catalytic mechanism of the enzyme, although their exact roles remain 
uncertain [6, 22-25].  Similar results were obtained when residues identified as important in the 
mechanism by a QM-MM study were varied (Arg-105, Glu-174 and Arg-228) [6, 26]. 
Galactokinase is also of interest due its role in the inherited metabolic disease type II galactosemia 
(OMIM #230200) [27-31].  This relatively mild genetic disease normally results in childhood cataracts 
which can be resolved by surgery or the exclusion of galactose (and precursors such as lactose) from 
the diet.  It is generally considered to have minimal longer term consequences, although this 
assumption has been questioned recently [27, 32].  Further interest comes from the proposal to 
target galactokinase in the treatment of type I and type III galactosemia [12, 27].  This would, in 
effect, convert these two severe diseases into the much milder type II galactosemia by reducing the 
build-up of α-D-galactose 1-phosphate which is assumed to be toxic.  Considerable progress has 
been made in the identification of inhibitors which are selective for human galactokinase and which 
show some promise in cell culture models [25, 33-36].  There has also been a recent suggestion that 
galactokinase inhibition may be a viable, novel chemotherapy for some forms of cancer [37]. 
  
We reasoned that if changes in the active site affected the dynamical and structural properties of 
other parts of the protein, the reverse may also be true and that this might be a useful approach 
when attempting the engineer the specificity of this enzyme.  In particular, we hypothesised that 
variations designed to change the flexibility of the region around residues 231-245 may affect the 
active site with consequences for catalysis.  We noted that previous work suggested that alterations 
to active site residues caused this region to be less likely to adopt an α-helical conformation [6].  
Therefore, we focussed on changes likely to reduce the α-helical propensity of this region.  We 
selected four residues in this region of human GALK1 and studied the effects of glycine and serine 
substitutions by molecular dynamics simulations.  The serine variants were also studied in in vitro 
kinetic and stability experiments in order to verify some of the in silico predictions.  This enabled us 
to demonstrate the concept that catalysis can be affected by variations designed to affect the 
dynamics of this protein.  The results broadly support our proposition and suggest an approach to 
enzyme engineering which might be more broadly applied. 
 
Materials and Methods 
Molecular dynamics 
Molecular dynamics (MD) simulations were carried out essentially as previously described [6, 8] 
using Amber 10 and the Amber Parm 99 forcefield [38].  The crystal structure of human 
galactokinase (PDB:  1WUU; chain A) was used as the basis for all simulations [39].  Residue 
numbering was based on the canonical protein sequence in Uniprot (P51570).  This structure was 
“cleaned” to remove selenomethione residues, fill gaps, convert AMP.PNP to ATP and minimise the 
energy as previously described [6].  The mutate feature in Biovia Discovery studio was used to 
generate variant structures.  Partial and RESP charges for the ligands (galactose, Mg2+ and ATP) were 
determined using the Gaussian 09 package and antechamber encoded in Amber 10 respectively [26, 
40, 41]. Before the simulation, the protein-ATP-galactose complex was soaked in a TIP3P water box 
(71.071 Å × 80.431 Å × 87.517 Å; minimum distance to the boundary of the protein, 8 Å) using tleap 
(as encoded in Amber 10). The system was neutralised by adding sodium ions.  The system was 
subjected to 1250 steps of First steepest descent minimisation (1250 steps) was carried out on the 
system, followed by conjugate gradient minimisation (carried out with a gradient of 0.5 kcal mol−1 
Å−2) [42]. The system was then heated (0-300 K for 50 ps; collision frequency of 5.0 ps−1) using the 
Langevin dynamics method [43]. The system was equilibrated using an NVT ensemble, a periodic 
boundary was applied and the system held at 300 K for 50 ps. Production simulation was then 
carried out at 300 K and 1 atm for 7 ns with a time step of 1 fs. The cut-off distance for Van der 
Waal’s interactions (calculated using the particle mesh Ewald method [44]) was 10 Å.  Hydrogen 
covalent bonds were constrained using SHAKE [45].  This length of simulation is consistent with 
recent studies on engineered proteins (for example, [46-49]). 
Simulations were monitored with perl (encoded in Amber).  The ptraj command in Amber 10 was 
used for secondary structure analysis and RMSF calculations. and structures visualised using Biovia 
Discovery Studio. Trajectories were visualised using VMD software and the timeline plugin was used 
to visualise secondary structure [50]. These were calculated using the equilibrated part of the 
trajectory (typically 2-4 ns), determined by monitoring RMSD over time (Supplementary Fig. S1) [51]. 
 
Expression, purification and mutagenesis of human galactokinase 
  
Human galactokinase was expressed in, and purified from, E. coli HMS174(DE3) as previously 
described [6, 8, 9, 23, 52].  Briefly, cultures (1 l) of recombinant bacteria were grown, lysed by 
sonication and galactokinase purified from the resulting extract by cobalt affinity chromatography 
(His-Select, Sigma, UK).  Purified protein was dialysed against 50 mM Hepes-OH, pH 7.5, 150 mM 
NaCl, 1 mM DTT, 10% (v/v) glycerol and stored, frozen in aliquots, at -80 °C.  Mutations of the coding 
sequence were made using the QuikChange method of site-directed mutagenesis [53].  All coding 
sequences were verified by DNA sequencing (GATC Biotech, London, UK). 
 
Galactokinase assay and kinetics 
Galactokinase activity was assayed by coupling the production of ADP to the reactions catalysed by 
pyruvate kinase (EC 2.7.1.4) and lactate dehydrogenase (EC 1.1.1.27).  This enables the reaction to 
be followed via the consumption of NADH and the consequent reduction in absorbance at 340 nm 
[6, 8, 54].  Reactions were carried out in a total volume of 160 µl in 96 well plates at 37 °C.  Assay 
mixes contained 50 mM Hepes-OH, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.4 mM 
phosphoenolpyruvate, 1 mM NADH, 10%(v/v) glycerol, pyruvate kinase (7.5 U), lactate 
dehydrogenase (10 U) and varying, sub-saturating amounts of ATP and galactose.  Reactions were 
initiated by the addition of enzyme (70 nM). They were arrayed in an eight by ten matrix so that 
galactose concentration varied along one axis and ATP concentration along the other.  This enabled 
the determination of eight Michaelis-Menten curves with sub-saturating galactose concentration 
and ten with sub-saturating ATP concentrations facilitating subsequent analysis.  It is known that 
human galactokinase has an ordered, ternary complex mechanism [52].  Therefore, each Michaelis-
Menten curve was analysed by non-linear curve fitting (as implemented in GraphPad Prism 6.0) to 
give apparent values for the Michaelis constant (Km,app) and the turnover number (kcat,app; equal to 
the maximum rate, Vmax,app, divided by the enzyme concentration).  These values were then used to 
determine the absolute values for the turnover number (kcat) and the two Michaelis constants (Km,ATP 
and Km,gal) according to the equation:  kcat,app=kcat[S]/(Km+[S]) where [S] is the substrate concentration 
[55].  The same approach was applied with monosaccharides other than galactose were used as a 
substrate. 
 
Analytical methods 
Protein concentrations were estimated by the method of Bradford, using BSA as a standard [56].  
Protein thermal stability was assessed using differential scanning fluorimetry (DSF) as previously 
described [6]. 
 
Results and Discussion 
Variation of residues 231-245 is predicted to affect the active site 
We focussed on four residues in this region – Leu-231, Gln-242, Glu-244 and Glu-245 (Figure 1a).  
Leucine, glutamine and glutamate residues were selected due to their high propensity towards α-
helical structure compared to serine and glycine [57].  In the crystal structure of human GALK1, the 
last three of these residues form part of an α-helix and the first part of a random coil structure which 
leads into this helix [39].  Leu-231 undergoes substantial structural and dynamic changes in response 
to active site residue variation, typically becoming more likely to be part of random coil structures 
  
[6].  Thus varying them to residues with lower α-helical propensity (i.e. glycine and serine) is likely to 
disrupt the helix, with potential effects on the active site and catalysis [57, 58].  Since glycine and 
serine also impart the greatest local flexibility on polypeptide chains, these variations are also likely 
to increase the mobility of the 231-245 region and may have wider implications for the overall 
dynamics of the protein [59].  It should be noted that Leu-231 is located in a less well-resolved 
region of the crystal structure.  This residue (and Ser-230) is missing in some chains and was 
modelled is the structure used in the simulations reported here (and in our previous work) [23].  
Thus the predictions concerning this residue should be viewed with greater caution than the others 
in this study. 
Variation of Leu-231 to glycine (L231G) was predicted to result in the initiation of the α-helix at 
residue 233 and reduced secondary structure propensity at residues 230 and 231 (Figure 2).  Analysis 
of the root mean squared fluctuation (RMSF) for the whole protein revealed that the region 230-245 
had substantially increased fluctuation, suggesting that this variation results in substantially greater 
mobility for the whole helical segment (Figure 3; Supplementary Figure S3).  The variation is also 
predicted to displace the helix comprising residues 260-265, which lies on the surface of the protein 
(data not shown).  Interestingly, this variant is predicted to increase the number of hydrogen bonds 
but not result in a significant change in the number of salt bridges in the protein (Table 1).  The 
effects of varying this residue to serine (L231S) are less dramatic, as might be expected since serine 
has lower flexibility than glycine [59].  Like L231G, this variant is predicted to initiate the helix at 
residue 233 (Figure 2; Figure 4a, left panel).  It also results in displacement of the helix comprising 
residues 171-180 (Figure 4a, right panel).  Note that this region includes Glu-174 which has 
previously been shown to be critical for the catalytic mechanism [6, 26].  The variant is predicted to 
result in a small reduction in the RMSF of the 230-245 region (Figure 3; Supplementary Figure S3).  It 
is predicted to result in no significant change in in the overall number of salt bridges, but no change 
in the number of hydrogen bonds (Table 1).  A new salt bridge involves a residue in the region under 
investigation (Glu-244 to Arg-248).  This interaction is created in all the variants studied here, except 
those involving Glu-244. This salt bridge results in a slight “kink” in the end of the α–helix.  
Paradoxically, it might be expected to rigidify this region of the protein, despite the introduction of a 
residue (serine) which is generally associated with increased local flexibility.  This new interaction 
may provide a partial explanation for the lack of expected effects on overall flexibility and catalysis 
(see below) of some of these variants. 
Variation of Gln-242 to glycine (Q242G) is predicted to result in initiation of the α-helix at residue 
237 (Figure 2).  The change is predicted to increase the RMSF towards the C-terminus of the protein 
(i.e. after residue ~300; Figure 3).It is also predicted to result in no significant change in the number 
of salt bridges and a decrease in the number of hydrogen bonds (Table 1).  Variation of this residue 
to serine (Q242S) also causes shortening of the α-helix by three residues (Figure 4b).  It is predicted 
to slightly decrease the RMSF in the 230-245 region, and to cause more substantial reductions in this 
parameter between residues 100 and 200 (Figure 3; Supplementary Figure S3).  Q242S is predicted 
to result in a decrease in the number of salt bridges but no change in the number of hydrogen bonds 
(Table 1). 
When Glu-244 was varied to glycine (E244G), the α-helix is predicted to initiate at residue 237 
(Figure 2).  Changes also occur in the 171-180 helix, which is displaced compared to the wild-type.  
The surface-exposed 261-265 helix is elongated to include residue 266 and the 255-259 turn is 
altered in conformation and displaced.  This variant has increased RMSF throughout the whole of the 
protein, suggesting a much more mobile and flexible structure (Figure 3).  The number of salt bridges 
is predicted not to change, and there is no change in the number of hydrogen bonds (Table 1).  
  
Variation of Glu-244 to serine (E244S) resulted in disruption to the first part of the 230-245 region 
with lower helical propensity in residues 230-236.  However, the C-terminal part of this region 
(which includes the varied residue) was not affected with 100% predicted α-helical conformation 
(Figure 2; Figure 4c, left panel).  The 171-180 helix is also disrupted but there was no predicted 
change in the 261-266 region (Figure 4c, right panel).  However, the overall RMSF of E244S is more 
similar to the wild-type in magnitude with some differences in the first 180 residues (Figure 3).  A 
decrease in the number of salt bridges and hydrogen bonds is predicted for this variant. 
Changing Glu-245 to glycine (E245G) also resulted in initiation of the α-helix at residue 237 (Figure 
2).  No changes were predicted in the 171-180 region, but similar changes to E244G were observed 
in the 255-266 region.  Interestingly, despite these changes, the RMSF in the 231-245 region was 
predicted to be reduced (Figure 3; Supplementary Figure S3).  The number of salt bridges was 
reduced (to the greatest extent of all the variants studied here) and the number of hydrogen bonds 
increased (Table 1).  Variation of this residue to serine (E245S) resulted in similar structural changes 
to E244S, with the 231-240 α-helix beginning at residue 236 (Figure 4d, left panel).  Unlike E245G, 
little change is predicted in the RMSF of the 231-245 region, but the 171-180 region is displaced 
including the catalytically important Glu-174 (Figure 3; Supplementary Figure S3; Figure 4d, right 
panel).  The number of salt bridges is unchanged and the number of hydrogen bonds is predicted to 
be increased (Table 1). 
In general, changing these residues to ones with lower α-helical propensity and increased backbone 
flexibility affected other parts of the protein.  Interestingly, in the case of changes to Gln-243 and 
Glu-244, there was no change in the immediate vicinity of the residue and the α-helix in which the 
residues are situated was not predicted to be disrupted.  Most of the variants resulted in a later start 
to this α-helix and an increased amount of other forms of secondary structure, including 310 helices, 
in residues 230-236.  There was no clear link between predicted changes in RMSF and the numbers 
of predicted salt bridges and hydrogen bonds. 
 
Activity and stability of four variants with altered mobility in the 230-245 region 
Previous work has shown that human galactokinase appears to be particularly sensitive to point 
mutations, with many resulting in insoluble or inactive enzyme [14, 52, 60].  Given this sensitivity, we 
focussed on the serine variants (L231S, Q242S, E244S and E245S) for experimental studies since 
these, in general, resulted in less radical changes to the overall dynamics of the protein [14, 52, 60].  
Each of these four variants could be expressed in, and purified from, E. coli with yields in the range 
1.0-1.5 mg protein per litre of culture (Supplementary Figure S2). 
All four variants were active galactokinases (Table 2; Figure 5).  Alteration of the dynamic behaviour 
of a helix adjacent to the active site would be expected to change the kinetic constants of the 
enzyme.  Broadly this is what was observed.  E244S had a significantly increased (five-fold) Michaelis 
constant for ATP, indicating that this variation impacts on the protein’s interaction with ATP.  Both 
E244S and E245S had significantly increased Michaelis constants for galactose indicating that 
variation of these two residues impacts galactose binding.  The turnover number was significantly 
increased for E244S, E245S and Q242S.  However, catalytic efficiency (as measured by the specificity 
constants, kcat/Km) was only significantly affected for galactose in E245S and L231S.  In both cases 
this measure was reduced indicating that these variants are less efficient at catalysing the 
phosphorylation of galactose than the wild-type.  Interestingly, in E244S, E245S and Q242S there is a 
trade-off between increased turnover number and increased Michaelis constants resulting in variant 
  
enzymes with either similar or slightly reduced catalytic efficiency when compared to wild-type 
galactokinase.  A similar trade-off was seen in previous studies on consensus variants [8]. 
We also tested the ability of these four variants to catalyse the phosphorylation of other known 
substrates of wild-type galactokinase – 2-deoxy-α-D-galactose, α-D-galactosamine and α-D-talose 
(the C2-epimer of galactose; Figure 1b).  With 2-deoxy-D-galactose, there was no significant change in 
the Michaelis constants for either ATP or the monosaccharide substrate with any of the variants 
(Table 2; Supplementary Figure S4).  For Q242S the turnover number and the catalytic efficiency 
with ATP were increased, whereas L231S had reduced turnover and decreased catalytic efficiency 
with both substrates.  Both L231S and Q242S were inactive with D-galactosamine, indicating these 
variations have implications for which substrates can be processed by the active site.  The two 
variants that were active with D-galactosamine were affected differently.  E245S was only 
significantly impacted in terms of the Michaelis constant for the sugar which was more than doubled 
(Table 2; Supplementary Figure S5).  E244S is more interesting, the Michaelis constant for ATP was 
significantly increased (four-fold), but kcat was nine-fold higher resulting in a slight, but not 
significant, increase in specificity constant for ATP (three-fold) and a significant increase (almost 
seven-fold) in the specificity constant for the sugar.  Variation of the 231-240 helix also impacts the 
phosphorylation of α-D-talose (Table 2; Supplementary Figure S6).  L231S was inactive with this sugar 
indicating that variation of this residue has implications for access of substrates to the active site.  
Compared to the wild-type, E244S was only significantly affected in terms of catalytic efficiency of 
the sugar (seven-fold decrease).  E245S had a significant increase in the Michaelis constant for ATP 
(almost four-fold), a significant increase in turnover number (over ten-fold), yet a significant 
reduction on catalytic efficiency for both ATP and the sugar (five-fold and seven-fold, respectively).  
Q242S had an increased Michaelis constant for the sugar (three-fold) and a doubled (but not 
significantly different) turnover number.  Both of these factors contribute to give different 
implications for the specificity constants:  the catalytic efficiency for ATP was significantly increased 
(three-fold), yet the catalytic efficiency for the sugar was significantly decreased (two-fold). 
The variants were also tested with other monosaccharide sugars as possible substrates.  However, 
like the wild-type, none of the variants showed any detectable activity with D-mannose, D-glucose, D-
fructose, L-glucose, L-mannose or L-arabinose as substrates (0.3 µM enzyme, 80 µM ATP and 2 mM 
monosaccharide; data not shown).  Several of these sugars have previously been shown to be 
substrates of different variant forms of human galactokinase [8, 9]. 
In addition to steady-state kinetics, we also investigated the stability of the four variants in terms of 
their resistance to chaotropic denaturation and to thermal denaturation.  The stability of each 
variant towards denaturants was determined by incubation with increasing concentrations of urea 
(Figure 6).  The wild-type proteins gave a discrete band up to 1 M Urea.  Only L231S behaved in a 
similar manner.  This is likely to be due to the localised effect of this variant on a small portion of the 
helix, as predicted from analysis of secondary structure.  Q242S was stable up to 0.5 M Urea; this is 
likely to be the result of more substantial changes to the protein’s structure.  E244S and E245S are 
unstable under these conditions even in the absence of urea, indicating a large effect of these 
variants on the protein, consistent with the molecular dynamics analysis of these two variants.  The 
melting temperature of each variant was determined using differential scanning flourimetry (Table 
3).  Broadly, results from this assay agree with those from the urea denaturation experiment. The 
melting temperature (Tm) of L231S was not significantly different to the wild-type protein.  Both 
E244S and E245S have significantly reduced Tm values compared to the wild-type.  However, Q242S 
has the lowest Tm value despite being relatively stable towards denaturation by urea. 
 
  
Conclusions 
Variations to the 231-245 region of human galactokinase do have an effect on catalysis at the active 
site.  However, they did not result in a broadening of the substrate specificity based on the range of 
monosaccharides tested.  The effects on catalysis were variable and not clearly correlated with 
changes predicted in the molecular dynamics simulations.  In general the effects were relatively 
small:  almost all changes in steady-state parameters were less than ten-fold.  Furthermore, the 
effects were not consistent between different monosaccharide substrates.  Indeed some variants 
had no detectable activity with α-D-galactosamine and α-D-talose, despite retaining reasonable 
activity with α-D-galactose (Table 2).  Human galactokinase is only known to show activity with α-D-
galactose and monosaccharides which differ at carbon-2 of the pyranose ring.  However, these 
variants appear to be able to tune the selectivity of the enzyme at this position enabling it to 
discriminate in favour of α-D-galactose.  The effects of these variations on protein stability were not 
straightforward.  Although the four serine variants all have reduced overall flexibility (as judged by 
RMSF plots, Figure 3; Supplementary Figure S3), three of them (Q242S, E244S and E245S) have 
significantly reduced thermal stability (Table 2).  Two (Q242S and E245S) are also less stable to 
chaotropic denaturation.  This suggests that reduced overall flexibility does not, necessarily, 
correlate with increased overall stability in human galactokinase which is consistent with studies on 
other enzymes [61].  Overall, these results support the hypothesis that variation of residues in this 
region have effects on catalysis and overall protein stability.  They also suggest that using molecular 
dynamics to identify sites in proteins which modulate global or local mobility may be a valuable 
approach to identify strategies to improve activity or change substrate ranges.  Such strategies might 
be used in conjunction with more “traditional” enzyme engineering approaches such as the rational 
modification of residues at the active site. 
 
Acknowledgements 
MM was in receipt of a PhD studentship funded by the Department for Employment and Learning, 
Northern Ireland (UK).  MH acknowledges financial support from InvestNI (Northern Ireland, UK; 
grant number: RD0314092).  We thank Queen’s University Belfast for access to the High 
Performance Computing Cluster and Prof Aaron Maule (School of Biological Sciences, Queen’s 
University Belfast) for access to qPCR machines used for DSF analyses.  
  
Figure legends 
Figure 1:  (a) Wild type GALK structure (PDB:  1WUU [39]) showing residues studied in this paper.  
Leu-231 is shown in red, Gln-242 in orange, Glu-244 in purple and Glu-245 in blue.  The substrates 
(ATP and galactose) are shown in the active site in stick format.  (b) Structures of the 
monosaccharide substrates of human galactokinase. 
Figure 2:  Molecular dynamics predicts effects on key regions of human galactokinase.  The 
percentage time spent in different forms of secondary structure for residues 230-244 in the wild-
type and variant forms of human galactokinase is shown in histogram format. These were 
determined using the every tenth frame from the entire stable trajectory and the ‘secstruct’ 
command of ‘ptraj’ in AmberTools.  
Figure 3:  Root mean square fluctuation (RMSF) of wild-type and variant galactokinases calculated 
using the ‘atomic fluct’ command of ‘ptraj’ in AmberTools on 2 ns of stable simulation. Wild-type 
values are shown in dashed red lines on each graph for comparison. 
Figure 4:  Key predicted, structural changes in variants of human galactokinase.  (a) Predicted 
changes in the L231S variant. Left, the 230-240 helix begins at residue 231, not 230.  Right, the 171-
180 helix adjacent to the active site is disrupted. The catalytically important residue Glu-174 is 
shown in stick form.  (b) Predicted changes in the Q242S variant. The 230-240 helix begins at residue 
233, not 230.  (c) Predicted changes in the E244S variant. Left, the 230-240 helix begins at residue 
237, not 230.  Right, the 171-180 helix adjacent to the active site is disrupted. The catalytically 
important residue Glu-174 is shown in stick form.  (d) Predicted changes in the E245S variant.  Left, 
the 230-240 helix begins at residue 236, not 230 and the helix is displaced compared to the wild-type 
protein.  Right, the 171-180 helix adjacent to the active site is disrupted. The catalytically important 
residue Glu-174 is shown in stick form.  These figures show the mean structure obtained using 
representative testcluster analysis of 2 equilibrated ns of simulation.  Five average clusters were 
produced from this timeframe and the cluster which represented the most frames chosen for 
comparison and display. 
Figure 5:  Steady-state kinetics analysis of wild-type and variant galactokinase with D-galactose as a 
substrate.  Apparent Vmax values are plotted against substrate concentration for each of the variants.  
The lines represent the non-linear curve fit calculated using GraphPad Prism 6.0.  Values shown are 
means ± standard error.  For all the variants 0.07 µM enzyme was used.  
Figure 6:  Native PAGE showing the results of exposure of wild-type and variant galactokinases to 
increasing concentrations of urea.  Enzymes (4.5 µM) were incubated at 37 °C for 30 min with 
increasing concentrations of Urea (shown above the gels), before loading onto a 15% native gel (pH 
8.8) and electrophoresed at 20 mA for 3 h.  A discrete band indicates a largely folded, non-denatured 
protein.  The disappearance of this band, or the blurring of the band is associated with chaotropic 
denaturation of the protein. 
  
  
Tables 
Table 1:  The number of predicted hydrogen bonds and salt bridges in wild-type and variant 
galactokinases. 
 
Variant Number of salt bridges Number of hydrogen bonds 
Wild-type 34 ± 4.7ns 87.3 ± 7.4 
L231G 33.8 ± 2.4ns 89.4 ± 7.6
*** 
L231S 31.6 ± 1.8ns 87.9 ± 7.7
ns 
Q242G 32.2 ± 2.4ns 82.8 ± 7.4
*** 
Q242S 30.4 ± 3.6* 87.6 ± 7.3
ns 
E244G 34.8 ± 3.6ns 88.0 ± 7.7
ns 
E244S 30.2 ± 2.8* 84.5 ± 7.4
*** 
E245G 28.4 ± 1.1*** 89.9 ± 7.9
*** 
E245S 32.2 ± 2.3ns 90.2 ± 7.7
*** 
 
The number of salt bridges was calculated using five frames from 1 ns of equilibrated trajectory, 
shown here are means and errors estimated as standard deviations of these means.  Mean numbers 
of hydrogen bonds present in each variant were calculated using 1 ns of stable trajectory and the 
‘hydrogen bonds’ plugin in VMD.  Error values shown are standard deviation. Significance of both 
data sets was determined using a one-way ANOVA and compared to WT using Dunnett’s post-test 
analysis in GraphPad Prism.  ns, not significant; *** p≤0.001 (n=1000); * p=≤0.05. 
 
  
Table 2:  Steady state kinetic data for variant galactokinases with various substrates.  
Monosaccharide substrate Variant Km,ATP 
(µM) 
Km,sugar 
(µM) 
kcat 
(s-1) 
kcat /Km,ATP 
(mM-1s-1) 
kcat /Km,sugar 
(mM-1s-1) 
D-Galactose Wild-type 3.9 ± 1.1 170 ± 30 1.7 ± 0.1 430 ± 110 10.1 ± 1.2 
 L231S 2.4 ± 0.5 260 ± 80 1.0 ± 0.1 360 ± 70 3.9 ± 1.1** 
 Q242S 9.4 ± 3.4 440 ± 70 5.9 ± 0.3*** 610 ± 200 13.5 ± 1.5 
 E244S 19.8 ± 7.1* 1000 ± 200** 6.1 ± 0.4*** 310 ± 90 6.2 ± 0.9 
 E245S 13.2 ± 2.6 1100 ± 120** 4.0 ± 0.2*** 300 ± 50 3.9 ± 0.3** 
2-Deoxy-D-galactose Wild-type 43.2 ± 5.6 970 ± 130 6.8 ± 0.4 190 ± 10 7.1 ± 0.6 
 L231S 14.8 ± 10.3 1100 ± 280 0.4 ± 0.1*** 30 ± 18** 0.5 ± 0.1*** 
 Q242S 44.6 ± 13.4 2700 ± 990 15.0 ± 4.0* 420 ± 110* 5.6 ± 0.7 
 E244S 36.7 ± 4.4 1800 ± 280 8.0 ± 1.0 210 ± 20 4.5 ± 0.5* 
 E245S 39.3 ± 12.2 1900 ± 540 11.0 ± 2.0 320 ± 60 5.8 ± 0.7 
D-Galactosamine Wild-type 16.2 ± 5.3 710 ± 180 2.1 ± 0.2 110 ± 250 2.9 ± 0.5 
 E244S 59.4 ± 25.2* 920 ± 150 18.1 ± 1.3*** 360 ± 80 19.7 ± 1.9*** 
 E245S 7.7 ± 4.0 2900 ± 910* 3.4 ± 0.5 440 ± 180 1.2 ± 0.1 
D-Talose Wild-type 16.2 ± 5.3 710 ± 180 1.7 ± 0.2 110 ± 25 2.9 ± 0.5 
  
 Q242S 12.8 ± 2.7 2300 ± 470* 3.4 ± 0.2 380 ± 70** 1.5 ±0.3* 
 E244S 6.6 ± 4.1 830 ± 380 0.5 ± 0.0 73 ± 42 0.4 ± 0.1*** 
 E245S 59.4 ± 2.5*** 920 ± 150 18.1 ± 1.3*** 20 ± 2* 0.4 ± 0.1*** 
 
All measurements taken using 0.07 µM of enzyme. Errors shown are standard errors, parameters were all estimated by fitting graphs of Vmax, app against 
substrate concentration as described in Materials and Methods using GraphPad Prism version 6.0. Significance calculated via one-way ANOVA and Dunnett 
post-test analysis to compare with wild-type parameters.  * p≤0.05; ** p≤0.01; *** p≤0.001; all other values not significantly different to wild-type.  Results 
with the wild-type enzyme and these substrates have been reported previously [6, 8]. 
 
  
Table 3:  Stability of variant galactokinases, as measured by differential scanning fluorimetry 
 
Variant Tm (°C) 
Wild-type 56.1 ± 0.3 
L231S 55.8 ± 0.1ns 
Q242S 52.7 ± 0.1*** 
E244S 55.1 ± 0.7** 
E245S 54.0 ± 0.4*** 
 
Variant enzyme (4.5 µM) was mixed with 5× sypro orange (manufacturer’s concentration definition).  
Readings were taken using a Rotor Gene Q qPCR machine from 25 °C to 95 °C in increments of 1 °C 
and steps of 5 s.  Melt analysis was used to determine Tm values.  Errors shown are standard 
deviation and significance was determined using a one-way ANOVA in GraphPad Prism (n=9). ns, not 
significant; ** p≤0.01; *** p≤0.001.  The result with the wild-type enzyme has been reported 
previously [6]. 
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Galactose + ATP → Galactose 1-phosphate + ADP 
 
Variation affects 
catalysis, specificity, 
stability and mobility 
  
 The specificity of galactokinase can be changed by altering active site mobility 
 Residues distant from the active site were studied:  Leu-231, Gln-242, Glu-244, Glu-245 
 Variation of these residues is predicted to alter protein mobility 
 These variations also affect specificity, stability and catalysis 
 This principle could be extended to other enzymes of biotechnological interest 
 
